Oral resveratrol and calcium fructoborate supplementation in subjects with stable angina pectoris: Effects on lipid profiles, inflammation markers, and quality of life

Nutrition

Volumn 29, Issue 1, 2013, Pages 178-183

  Militaru, Constantin ^a   Donoiu, Ionut ^b   Craciun, Alina ^a   Scorei, Iulia Daria ^c   Bulearca, Anca Mihaela ^d   Scorei, Romulus Ion ^e  

^a Craiova Cardiology Center   (Romania)

^b UNIVERSITY OF MEDICINE AND PHARMACY OF CRAIOVA   (Romania)

^c Neuropsychiatry Hospital   (Romania)

^d Bioboron Research Institute from Natural Research Ltd   (Romania)

^e UNIVERSITY OF CRAIOVA   (Romania)

Author keywords

Angina pectoris; Calcium fructoborate; Dietary supplementation; Double blinded pilot study; Resveratrol; Systemic inflammation

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; CALCIUM FRUCTOBORATE; CARDIOVASCULAR AGENT; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; RESVERATROL; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG MIXTURE; DRUG POTENTIATION; FEMALE; HUMAN; LIPID COMPOSITION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; STABLE ANGINA PECTORIS; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; AGED; ANGINA, STABLE; BORATES; C-REACTIVE PROTEIN; DIETARY SUPPLEMENTS; DOUBLE-BLIND METHOD; FEMALE; FRUCTOSE; HUMANS; INFLAMMATION MEDIATORS; LIPIDS; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; QUALITY OF LIFE; STILBENES;

ANGINA;

EID: 84870851275     PISSN: 08999007     EISSN: 18731244     Source Type: Journal    
DOI: 10.1016/j.nut.2012.07.006     Document Type: Article

References (40)

1. LaRosa J.C. Future cardiovascular endpoint studies: where will the research take us?. Am J Cardiol 1999, 84:545-548.
2. René R., Packard S., Libby P. Inflammation in atherosclerosis: from vascular biology to biomarker discovery and risk prediction. Clin Chem 2008, 54:24-38.
3. Fan E., Zhang L., Jiang S., Bai Y., Fan E., Zhang L. Beneficial effects of resveratrol on atherosclerosis. J Med Food 2008, 11:610-614.
4. Hattori R., Otani H., Maulik N., Das D.K. Pharmacological preconditioning with resveratrol: role of nitric oxide. Am J Physiol Heart Circ Physiol 2002, 282:H1988-H1995.
5. Juric D., Wojciechowski P., Das D.K., Netticadan T. Prevention of concentric hypertrophy and diastolic impairment in aortic-banded rats treated with resveratrol. Am J Physiol Heart Circ Physiol 2007, 292:H2138-H2143.
6. Csiszar A., Labinskyy N., Olson S., Pinto J.T., Gupte S., Wu J.M., et al. Resveratrol prevents monocrotaline-induced pulmonary hypertension in rats. Hypertension 2009, 54:668-675.
7. Zhang H., Morgan B., Potter B.J., Ma L., Dellsperger K.C., Ungvari Z., et al. Resveratrol improves left ventricular diastolic relaxation in type 2 diabetes by inhibiting oxidative/nitrative stress. Am J Physiol Heart Circ Physiol 2010, 299:H985-H994.
8. Burstein B., Maguy A., Clement R., Gosselin H., Poulin F., Ethier N., et al. Effects of resveratrol (trans-3,5,4-trihydroxystilbene) treatment on cardiac remodeling following myocardial infarction. J Pharmacol Exp Ther 2007, 323:916-923.
9. Walle T., Hsieh F., DeLegge M.H., Oatis J.E., Walle U.K. High absorption but very low bioavailability of oral resveratrol in humans. Drug Metab Dispos 2004, 32:1377-1382.
10. Nielsen F., Meacham S. Growing evidence for human health benefits of boron. J Evid Based Complement Alternat Med 2011, 16:169-180.
11. Scorei R.I., Rotaru P. Calcium fructoborate-potential anti-inflammatory agent. Biol Trace Elem Res 2011, 143:1223-1238.
12. Rotaru P., Scorei R., Harabor A., Dumitru M.D. Thermal analysis of a calcium fructoborate sample. Thermochim Acta 2010, 506:8-13.
13. Scorei R., Ciubar R., Iancu C., Mitran V., Cimpean A., Iordachescu D. In vitro effects of calcium fructoborate on fMLP stimulated human neutrophil granulocytes. Biol Trace Elem Res 2007, 118:27-37.
14. Scorei R.I., Ciofrangeanu C., Ion R., Cimpean A., Galateanu B., Mitran V., et al. In vitro effects of calcium fructoborate upon production of inflammatory mediators by LPS-stimulated RAW 264.7 macrophages. Biol Trace Elem Res 2010, 135:334-344.
15. Scorei R., Mitrut P., Petrisor I., Scorei I.D. A double-blind, placebo-controlled pilot study to evaluate the effect of calcium fructoborate on systemic inflammation and dyslipidemia markers for middle-aged people with primary osteoarthritis. Biol Trace Elem Res 2011, 144:253-263.
16. Reyes-Izquierdo T., Nemzer B., Gonzalez A.E., Zhou Q., Argumedo R., Shu C., et al. Short-term intake of calcium fructoborate improves WOMAC and McGill scores and beneficially modulates biomarkers associated with knee osteoarthritis: a pilot clinical double-blinded placebo-controlled study. Am J Biomed Sci 2012, 4:111-122.
17. Mitrut P, Burada F, Rogoz I, Genunche-Dumitrescu A. Experimental studies in vivo regarding the effect of resveratrol extracted from vine on gastric neoplastic injuries. Unpublished data. Romanian grant 954/2007, type A CNCSIS. 2007-2009.
18. European Union 2002. 2002/72/CE Commission directive of 6 August 2002 relating to plastics materials intended to come into contact with plastics, Official Journal of European Communities, nr. L220 of 15.08.2002, p.18.
19. Talbott S.M., Hughes K. The health professional's guide to dietary supplements 2006, Lippincott Williams & Wilkins, Philadelphia. 1st ed.
20. Boocock D.J., Faust G.E., Patel K.R., Schinas A.M., Brown V.A., Ducharme M.P., et al. Phase I dose escalation pharmacokinetic study in healthy volunteers of resveratrol, a potential cancer chemopreventive agent. Cancer Epidemiol Biomarkers Prev 2007, 16:1246-1252.
21. Nissen S.E., Nicholls S.J., Sipahi I., Libby P., Raichlen J.S., Ballantyne C.M., et al. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA 2006, 295:1556-1565.
22. Spertus J.A., Winder J.A., Dewhurst T.A., Deyo R.A., Fihn S.D. Monitoring the quality of life in patients with coronary heart disease. Am J Cardiol 1994, 74:1240-1244.
23. Spertus J.A., Winder J.A., Dewhurst T.A., Deyo R.A., Prodzinski J., McDonell M., et al. Development and evaluation of the Seattle Anginal Questionnaire: a new functional status measure for coronary artery disease. J Am Coll Cardiol 1995, 25:333-341.
24. Paoletti R., Gotto A.M., Hajjar D.P. Inflammation in atherosclerosis and implications for therapy. Circulation 2004, 109:III-20-III-26.
25. DeJongste MJL, A Tio R, D Foreman R. Chronic therapeutically refractory angina pectoris. Heart 2004;90:225-30.
26. Meletis C.D. Dietary and lifestyle interventions for a healthy heart. J Altern Complement Med 1998, 4:333-337.
27. Tangney C.C., Rosenson R.S. Nutritional antioxidants in coronary heart disease. UpToDate October 2008, BDR, Inc., Wellesley, MA. B. Rose (Ed.).
28. Miljkovic D., Scorei I.R., Cimpoiasu V.M., Scorei I.D. Calcium fructoborate: plant-based dietary boron for human nutrition. J Diet Suppl 2009, 6:211-226.
29. Robb E.L., Page M.M., Wiens B.E., Stuart J.A. Molecular mechanisms of oxidative stress resistance induced by resveratrol: specific and progressive induction of MnSOD. Biochem Biophys Res Commun 2008, 367:406-412.
30. EFSA Opinion of the scientific panel on dietetic products, nutrition and allergies on a request from the commission related to the tolerable upper intake level of boron (sodium borate and boric acid). EFSA J 2004, 80:1-22.
31. USEPA (2004) Toxicological review of boron and compounds. (CAS No. 7440-42-8) In Support of Summary Information on the Integrated Risk Information System (IRIS) EPA 635/04/052 US Environmental Protection Agency, Washington D.C. June 2004. http://www.epa.gov/iris.
32. Nielsen F.H., Mullen L.M., Nielsen E.J. Dietary boron affects blood cell counts and hemoglobin concentrations in humans. J Trace Elem Exp Med 1991, 4:211-223.
33. Tapparelli C., Metternich R., Ehrhardt C., Zurini M., Claeson G., Scully M.F., et al. In vitro and in vivo characterization of a neutral boron-containing thrombin inhibitor. J Biol Chem 1993, 268:4734-4741.
34. Nielsen F.H. Boron deprivation decreases liver S-adenosylmethionine and spermidine and increases plasma homocysteine and cysteine in rats. J Trace Elem Med Biol 2009, 23:204-213.
35. Bakken N.A., Hunt C.D. Dietary boron decreases peak pancreatic in situ insulin release in chicks and plasma insulin concentrations in rats regardless of vitamin D or magnesium status. J Nutr 2003, 133:3577-3583.
36. van Kimmenade R.R.J., Bakker J.A., Crijns H.J.G.M., van Dieijen-Visser M.P., Pinto Y.M. The value of (NT-pro) BNP in the diagnosis, prognosis and treatment of congestive heart failure. Neth Heart J 2004, 12:61-63.
37. Danchin N. C-reactive protein for risk assessment in coronary artery disease. Heart 2010, 96:325-327.
38. Mukoyama M., Nakao K., Hosoda K., Suga S., Saito Y., Ogawa Y., et al. Brain natriuretic peptide as a novel cardiac hormone in humans. Evidence for an exquisite dual natriuretic peptide system, atrial natriuretic peptide and brain natriuretic peptide. J Clin Invest 1991, 87:1402-1412.
39. Wiersma J.J., van der Zee P.M., van Straalen J.P., Fischer J.C., van Eck-Smit B.L., Tijssen J.G., et al. NT-pro-BNP is associated with inducible myocardial ischemia in mildly symptomatic type 2 diabetic patients. Int J Cardiol 2010, 145:295-296.
40. Lee Y.S., Kim K.S., Lee J.B., Ryu J.K., Choi J.Y., Kim B.K., et al. Effect of valsartan on N-terminal pro-brain natriuretic peptide in patient with stable chronic heart failure: comparison with enalapril. Korean Circ J 2011, 41:61-67.